Zobrazeno 1 - 10
of 748
pro vyhledávání: '"Massimo, Franchini"'
Publikováno v:
Life, Vol 14, Iss 9, p 1207 (2024)
Italy was the first western country to be hit by the COVID-19 pandemic and has suffered nearly 200,000 deaths so far during the four years of the pandemic. In March 2020, Italy first deployed COVID-19 convalescent plasma (CCP) to treat hospitalized p
Externí odkaz:
https://doaj.org/article/3d20d4ee54a944348e60d4f8216d13d3
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/580265dc8f384ec499e80fc59669f54f
Autor:
Jonathon W. Senefeld, PhD, Ellen K. Gorman, BS, Patrick W. Johnson, BS, M. Erin Moir, PhD, Stephen A. Klassen, PhD, Rickey E. Carter, PhD, Nigel S. Paneth, MD, David J. Sullivan, MD, Olaf H. Morkeberg, BA, R. Scott Wright, MD, DeLisa Fairweather, PhD, Katelyn A. Bruno, PhD, Shmuel Shoham, MD, Evan M. Bloch, MBChB, MS, Daniele Focosi, MD, Jeffrey P. Henderson, MD, PhD, Justin E. Juskewitch, MD, PhD, Liise-Anne Pirofski, MD, Brenda J. Grossman, MD, MPH, Aaron A.R. Tobian, MD, PhD, Massimo Franchini, MD, Ravindra Ganesh, MBBS, MD, Ryan T. Hurt, MD, PhD, Neil E. Kay, MD, Sameer A. Parikh, MBBS, Sarah E. Baker, PhD, Zachary A. Buchholtz, BS, Matthew R. Buras, BS, Andrew J. Clayburn, BS, Joshua J. Dennis, BS, Juan C. Diaz Soto, MD, Vitaly Herasevich, MD, PhD, Allan M. Klompas, MB, BCh, BAO, Katie L. Kunze, PhD, Kathryn F. Larson, MD, John R. Mills, PhD, Riley J. Regimbal, BS, Juan G. Ripoll, MD, Matthew A. Sexton, MD, John R.A. Shepherd, MD, James R. Stubbs, MD, Elitza S. Theel, PhD, Camille M. van Buskirk, MD, Noud van Helmond, MD, Matthew N.P. Vogt, MD, Emily R. Whelan, BS, Chad C. Wiggins, PhD, Jeffrey L. Winters, MD, Arturo Casadevall, MD, PhD, Michael J. Joyner, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 7, Iss 5, Pp 499-513 (2023)
Objective: To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19. Patients and Methods: On October 26, 2022, a systematic search was performe
Externí odkaz:
https://doaj.org/article/dadeeaf646b74fc8991c25a417a35f18
Publikováno v:
Life, Vol 14, Iss 7, p 792 (2024)
Background: Sample size estimation is an essential step in the design of randomized controlled trials (RCTs) evaluating a treatment effect. Sample size is a critical variable in determining statistical significance and, thus, it significantly influen
Externí odkaz:
https://doaj.org/article/9b19fd101a68434dac1df284b0fbd64d
Autor:
Massimo Franchini
Publikováno v:
Bleeding, Thrombosis and Vascular Biology, Vol 2, Iss 4 (2023)
Polycythemia vera (PV) is a chronic Philadelphia-negative myeloproliferative neoplasm caused by JAK2 mutation and characterized predominantly by the overproduction of red blood cells. The current treatment strategies of PV are based on periodic phleb
Externí odkaz:
https://doaj.org/article/6b5e5fc678b3461fa51f5e607e58ccae
Publikováno v:
Haematologica, Vol 109, Iss 4 (2023)
D-dimer, a soluble fibrin degradation product that originates from plasmin-induced degradation of cross-linked fibrin, is an important biomarker of coagulation activation and secondary fibrinolysis that is routinely used to rule out venous thromboemb
Externí odkaz:
https://doaj.org/article/514eacf085404729b613a83a28666bed
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Although COVID-19 convalescent plasma is commonly used for the treatment of immunosuppressed patients, this approach has yielded mixed results. Here, the authors present a systematic review of Omicron-neutralization data in convalescent plasma from v
Externí odkaz:
https://doaj.org/article/a35300fdd72b4d839ff6ff2f5382d50d
Autor:
Massimo Franchini, Daniele Focosi, Mario Cruciani, Michael J. Joyner, Liise-anne Pirofski, Jonathon W. Senefeld, Shmuel Shoham, David J. Sullivan, Arturo Casadevall
Publikováno v:
Diseases, Vol 12, Iss 3, p 41 (2024)
Plasma collected from people recovered from COVID-19 (COVID-19 convalescent plasma, CCP) was the first antibody-based therapy employed to fight the pandemic. CCP was, however, often employed in combination with other drugs, such as the antiviral remd
Externí odkaz:
https://doaj.org/article/d2239de120eb4f31855e94379cda009b
Autor:
Massimo Franchini, Daniele Focosi
Publikováno v:
Life, Vol 14, Iss 2, p 214 (2024)
Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repur
Externí odkaz:
https://doaj.org/article/a557aee46abb45b498954bf80e0dbf97
Publikováno v:
Viruses, Vol 16, Iss 2, p 217 (2024)
Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was the most successful in having the longest temporal window of clinical use, showing a high degree of resiliency to SARS-CoV-2 evolution interrupted only by the appe
Externí odkaz:
https://doaj.org/article/3746f4b213234f0bbe629268893ad258